ASH 2021 | HMA in combination with venetoclax and magrolimab in the treatment of AML
David Sallman
• 11 Dec 2021
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, highlights some interesting data from a Phase II study investigating the use of hypomethylating agent (HMA) plus venetoclax and magrolimab in the treatment of both frontline acute myeloid leukemia (AML) patients, as well as relapsed/refractory (R/R) AML patients (NCT04778410). Dr Sallman discusses some of the results from this promising study, drawing focus on p53-mutated patients and the early responses observed. To conclude, Dr Sallman introduces another Phase III trial, ENHANCE-3, which will investigate triplet therapy versus the HMA plus venetoclax doublet therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
